Overview

Controlled Trial: 5-day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
0
Participant gender:
All
Summary
New antibiotics are required to have not only the antibacterial activity against doxycyline-resistant O. tsutsugamushi but also lower risk for resistance or any cross-resistance to others. In this prospective, open-label, randomized trial, we enroll patients with mild-to-moderate scrub typhus. We compared the efficacy and safety of a 5-day rifampin therapy with those of a 5-day doxycycline therapy at Chosun University Hospital, or one of its two community-based affiliated hospitals which are all located in southwestern Korea between 2006 and 2009.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Chosun University Hospital
Dong-Min Kim
Treatments:
Doxycycline
Rifampin
Criteria
Inclusion Criteria:

Inclusion criteria were:

- Adults aged 18 years or older

- A fever of higher than 37.5°C

- The concurrent presence of eschar or a maculopapular skin rash; and the clear presence
of more than two symptoms such as headache, malaise, myalgia, coughing, nausea and
abdominal discomfort.

- Patients were hospitalized at Chosun University Hospital in Kwangju, Korea or one of
its two community-based affiliated hospitals which are all located in southwestern
Korea between 2006 and 2009.

Exclusion Criteria:

The exclusion criteria were:

- An inability to take oral medications

- Pregnancy

- Hypersensitivity to the trial drugs

- Previous drug therapy with potential antirickettsial activity (e.g., rifampicin,
chloramphenicol, macrolides, fluoroquinolones or tetracyclines) within 48 h prior to
admission

- Severe scrub typhus (shock requiring vasopressor therapy for more than one hour

- A stuporous or comatose level of consciousness

- Respiratory failure requiring mechanical ventilation or renal failure requiring
immediate dialysis) (4, 10).

- For the differential diagnosis of scrub typhus from other diseases with similar
symptoms (e.g., murine typhus, leptospirosis, hemorrhagic fever with renal syndrome
and systemic lupus erythematosus), patients underwent diagnostic tests. We thus
excluded patients with concurrent infections who had the risk of causing different
outcomes.